Evidence map›Paper›PMID 39628622›Full record

ArticleIntractable & rare diseases research2024

The value of contrast-enhance ultrasound in the diagnosis of hepatic post-transplant lymphoproliferative disease: Four case reports.

Xingqi Lu, Jingtong Yu, Litao Ruan, Kazushi Numata, Dong Zhang, Feiqian Wang

Abstract read
In one paragraph

Article in Intractable & rare diseases research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xingqi LuDepartment of Ultrasound, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.
Jingtong YuDepartment of Ultrasound, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.
Litao RuanDepartment of Ultrasound, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.
Kazushi NumataGastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
Dong ZhangDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.
Feiqian WangDepartment of Ultrasound, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-transplant lymphoproliferative disease (PTLD) is a rare but life-threatening disease that occurs after organ transplantation. Histopathology is the gold standard for the diagnosis of PTLD. Because of its rarity and atypical symptoms, many patients are misdiagnosed with liver abscess, liver cancer, or missed diagnosis long before pathological diagnosis is obtained, thus delaying treatment. Early and accurate diagnosis, in addition to histopathological examination, is difficult. Contrast-enhanced ultrasound (CEUS) imaging techniques have overwhelming advantages of being safe (noninvasive, radiation-free) and sensitive for evaluating the microcirculation of lesions, thus making them widely used in the diagnosis of hepatic lesions. Unfortunately, there are few reports of CEUS data on hepatic PTLD (HPTLD). This study reported and analyzed four cases of HPTLD in detail, all of which underwent pre-biopsy CEUS examinations and had a complete diagnosis and treatment process. By offering readers comprehensive knowledge of CEUS in the diagnosis of HPTLD, our study aims to help reduce misdiagnoses and missed diagnoses, thereby improving patient treatment and prognosis.

Indexed as

contrast-enhanced ultrasounddiagnosisimagepost-transplant lymphoproliferative diseasetransplant liver

Identifiers

PMID39628622
PMCPMC11609044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.